Football Greats Join Parent Project Muscular Dystrophy at Wine Tasting Event
Posted on: Thursday, 30 April 2009, 15:00 CDT
Former
(Logo: http://www.newscom.com/cgi-bin/prnh/20081009/DC38130LOGO)
Pour for a Cure is the first event hosted by Duchenne FACES of
Duchenne is the most common fatal genetic disorder diagnosed during early childhood. A progressive muscle disorder that causes loss of muscle function and independence, Duchenne affects approximately one out of every 3,500 boys worldwide. Duchenne can occur during any pregnancy regardless of family history. To date, there is no cure or treatment to stop the progression of Duchenne, and young men with Duchenne typically live only into their twenties. But there is hope.
Ms. Furlong is thrilled with the success of the Duchenne FACES program, and is particularly proud of the efforts of the
Both
that process along."
Mr. Oates, who also knows the Garofalos, agrees, "It's a no-brainer. When you care about people -- not just people you know or people that are related to you, but people in general -- you have to help. Duchenne is a horrible disease. But you'd never know it from the kids I meet who are battling this thing. Their spirit and passion for life is inspiring. If they can fight, then I can fight."
This inaugural Pour for a Cure event will boast an impressive wine list of over 200 selections, along with beer and spirits, thanks to Vine Republic in
About PPMD
Parent Project Muscular Dystrophy (PPMD) is a national not-for-profit organization founded in 1994 by parents of children with Duchenne and Becker muscular dystrophy. The organization's mission is to improve the treatment, quality of life and long-term outlook for all individuals affected by Duchenne muscular dystrophy through research, advocacy, education and compassion. Only this comprehensive approach will lead to the day that 100% of those diagnosed can turn to a treatment that will end Duchenne. PPMD is headquartered in
SOURCE Parent Project Muscular Dystrophy
Source: PR Newswire
Related Articles
- Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy
- Parent Project Muscular Dystrophy Wins Vote For A Cause Contest on Intel's Facebook Page
- Parent Project Muscular Dystrophy Holds 15th Annual Connect Conference in Atlanta
- PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
- PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
- Stem Cells May Ease Muscular Dystrophy
- Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine
- AVI BioPharma Introduces ESPRIT With Initial Application in Muscular Dystrophy
- Fatigue, Decreased Interest in Play, Motor Delay, and Elevated Liver- Function Tests in a 4-Year-Old Boy*
User Comments (0)

RSS Feeds